Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features
- Authors: Kalmykova ZA1, Kononenko IV1, Mayorov AY.1
-
Affiliations:
- Endocrinology Research Centre
- Issue: Vol 91, No 12 (2019)
- Pages: 115-121
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33755
- DOI: https://doi.org/10.26442/00403660.2019.12.000166
- ID: 33755
Cite item
Full Text
Abstract
Diabetes mellitus (DM) and chronic liver disease (CLD) are pathological conditions associated with each other and reaching epidemic proportions. There is a strong pathogenetic relationship of carbohydrate metabolism disorders and a number of CLD. Common mechanisms that provoke metabolic and autoimmune disorders in the development of various CLD, leading to steatosis, insulin resistance (IR), impaired glucose tolerance and the development of DM are described. Effective glycemic control can have a beneficial effect on the treatment of these patients, and, conversely, there is evidence of a positive effect of CLD therapy on carbohydrate metabolism. This review discusses the correction of carbohydrate metabolism in patients with CLD, the main groups of modern hypoglycemic drugs, mechanisms of their action, the impact on the physiology of the liver, the possibility of using each of these pharmacological groups in patients with impaired liver function. The modern approaches and possibilities of drug effects on the process of fibrogenesis in CLD, the effect of these drugs on carbohydrate metabolism are listed.
Full Text
##article.viewOnOriginalSite##About the authors
Z A Kalmykova
Endocrinology Research CentreMoscow, Russia
I V Kononenko
Endocrinology Research CentreMoscow, Russia
A Yu Mayorov
Endocrinology Research CentreMoscow, Russia
References
- Gupta N.K, Lewis J.H. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther. 2008;28(9):1021-41. doi: 10.1111/j.1365-2036.2008.03822.x1
- Дедов И.И., Шестакова М.В. Cахарный диабет типа 2. От теории к практике. М., 2016.
- British National Formulary (BNF) 70. Published 2015. Available at: https://pharm.reviews/images/statyi/british-national-formulary-2015.pdf (accessed Aug 7, 2018).
- Арутюнов А.Т., Иваников И.О., Сюткин В.Е. Диагностика и лечение хронических заболеваний печени. М.: Принт-Ателье, 2005. 303 с. ISBN 5-98107-020-X.
- Zhang X, Harmsen W.S, Mettler T.A, et al. Continuation of metformin use after a diagnosisь of cirrhosis significantly improves survival of patients with diabetes. Hepatology. 2014;60(6):2008-16. doi: 10.1002/hep.27199
- Khan R, Foster R, Chowdhury A. Managing Diabetes in Patients with Chronic Liver Disease. Postgrad Med. 2012;124(4):130-7. doi: 10.3810/pgm.2012.07.2574
- Gangopadhyay K.K. Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. Indian J Endocr Metab. 2017. doi: 10.4103/ijem.IJEM
- Baliunas O, Taylor J, Irving H, et al. Alcohol as a Risk Factor for Type 2 Diabetes. Diabetes Care. 2009;32(11):2123-32. doi: 10.2337/dc09-0227
- Bhat A. Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol. 2015;7(12):1652. doi: 10.4254/wjh.v7.i12.1652
- Kawamori R, Kadowaki T, Onjic M, et al. Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan. Diabetes Res Clin Pract. 2007;76(2):229-35.
- Bril F, Kalavalapalli S, Clark V.C, Lomonaco R.S. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol. 2018;16(4):558-66.
- Регистр лекарственных средств России РЛС [Electronic resource]. Доступно по ссылке: https://www.rlsnet.ru (дата обращения: 07.08.2018)
- Tolman K.G, Fonseca V, Dalpiaz A, Tan M.H. Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease. Diabetes Care. 2007;30(3):734-43. doi: 10.2337/dc06-1539
- Gentile S, Turco S, Guarino G, et al. Effect of treatment with acarbose and insulin in patients with non - insulin - dependent diabetes mellitus associated with non - alcoholic liver cirrhosis. Diabetes Obes Metab. 2001;3(1):33-40.
- Gentile S, Guarino G, Romano M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol. 2005;3(2):184-91.
- Cosmi F, Shen L, Magnoli M, et al. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail. 2018;20(5):888-95. doi: 10.1002/ejhf.1146
- Kupčová V, Arold G, Roepstorff C, et al. Insulin degludec: Pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig. 2014;34(2):127-33. doi: 10.1007/s40261-013-0154-1
- Gentile S, Guarino G, Strollo F, et al. Lispro insulin in people with non - alcoholic liver cirrhosis and type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016;113:179-86. doi: 10.1016/j.diabres.2015.12.006
- García-Compeán D, González-González J.A, Lavalle-González F.J, et al. Hepatogenous diabetes: Is it a neglected condition in chronic liver disease? World J Gastroenterol. 2016;22(10):2869-74. doi: 10.3748/wjg.v22.i10.289
- Scheen A.J. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin - based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53(9):773-85. doi: 10.1007/s40262-014-0157-y
- Giorda C.B, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine. 2014;46(3):406-19. doi: 10.1007/s12020- 014- 0179-0
- Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2017;20(1S):1-112. doi: 10.14341/DM20171S8
- Ивашкин В.Т., Ющук М.В. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению взрослых больных гепатитом В. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;(3):5-19.
- Morales A.L, Junga Z, Singla M.B, et al. Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. World J Hepatol. 2016;8(35):1557-63. doi: 10.4254/wjh.v8.i35.1557
- Ikeda A, Ikeda K, Takai A, et al. Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c. Digestion. 2017;96(4):228-30. doi: 10.1159/000484237
- Hammerstad S.S, Grock S.F, Lee H.J, Hasham A. Diabetes and hepatitis C: a two - way association. Front Endocrinol. 2015;6(September). doi: 10.3389/fendo.2015.00134
- Li Q, Xu B, Michie S.A, Rubins K.H, et al. Interferon alpha initiates type 1 diabetes in nonobese diabetic mice. PNAS. 2008;105(34):12439-44.
- Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации Российского общества по изучению печени по ведению взрослых пациентов с алкогольной болезнью печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(6):20-40. doi: 10.22416/1382-4376-2017-27-6-20-40
- Han S.J, Kim H.J, Kim D.J, et al. Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double - blind multicenter study. Diabetol Metab Syndr. 2015;7:64. doi: 10.1186/s13098-015-0060-1
- Chalasani N, Younossi Z, Lavine J.E, et al. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57.
- Mudaliar S, Robert R, Henry A.J.S. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2013;145(3):574-82. doi: 10.1053/j.gastro.2013.05.042
- Смирнова О.М. Сахарный диабет и неалкогольная болезнь печени. Медицинский альманах. 2014:57-61
- Скляник И.А., Шамхалова М.Ш., Шестакова М.В. Посттрансплантационный сахарный диабет. Обзор литературы. Сахарный диабет. 2015;18(2):20-31